Clinical, functional and therapeutic evaluation of CFTR variant I507del
Journal of Cystic Fibrosis · 2026-07 · 25 (4) · 745-752
DOI: 10.1016/j.jcf.2026.02.013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2026-07. Verfasst von Neeraj Sharma und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: nsharma5@jh.edu. Hauptthemen laut MEDLINE: Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases, Vertex Pharmaceuticals Incorporated.
Abstract (Originalsprache)
Small-molecule CFTR modulators target variants that allow CFTR protein production, but clinically relevant response depends on modulator effectiveness. One such variant is I507del (p.Ile507del, c.1519_1521delATC) and its location (adjacent to F508del) may encourage empirical treatment with modulators. Consequently, we have performed studies to inform management of individuals with CF bearing I507del. CFTR2 lists 704 individuals with I507del and a severe variant, with clinical features like F508del homozygotes (pancreatic insufficiency 96%, mean ppFEV1 70%, mean sweat chloride 102 mM). In primary human nasal epithelial (HNE) cultures from two donors carrying I507del and a null variant (2184delA or 621+1G>T), baseline CFTR activity was
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: nsharma5@jh.edu.
- Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, UK.
- Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- Children's Hospital of Philadelphia and University of Pennsylvania Perelman School of Medicine, Philadelphia, PA USA.
- Department of Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore MD, USA.
Förderung
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
- Vertex Pharmaceuticals Incorporated
- Cystic Fibrosis Foundation Therapeutics Inc
Zitieren
APA
Sharma, N., Starego, K., Li, H., Kleist, A. B., Cox, G., Havens, M., Neneh, J. S., Parr, A., Merlo, N. A., Ren, C. L., Vanscoy, L., Raraigh, K. S., Merlo, C., Sheppard, D. N., & Cutting, G. R. (2026). Clinical, functional and therapeutic evaluation of CFTR variant I507del. Journal of Cystic Fibrosis, 25(4), 745-752. https://doi.org/10.1016/j.jcf.2026.02.013
Vancouver
Sharma N, Starego K, Li H, Kleist AB, Cox G, Havens M, et al. Clinical, functional and therapeutic evaluation of CFTR variant I507del. Journal of Cystic Fibrosis. 2026;25(4):745-752. doi:10.1016/j.jcf.2026.02.013
BibTeX
@article{Sharma2026,
author = {Sharma, Neeraj and Starego, Katherine and Li, Hongyu and Kleist, Andrew B and Cox, Gabrielle and Havens, Madison and Neneh, Jalloh S and Parr, Alianna and Merlo, Nicholas A and Ren, Clement L and Vanscoy, Lori and Raraigh, Karen S and Merlo, Christian and Sheppard, David N and Cutting, Garry R},
title = {Clinical, functional and therapeutic evaluation of CFTR variant I507del},
journal = {Journal of Cystic Fibrosis},
year = {2026},
volume = {25},
number = {4},
pages = {745--752},
doi = {10.1016/j.jcf.2026.02.013}
}
EUVIMED